Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) Reaches New 52-Week High – Time to Buy?

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY)’s stock price reached a new 52-week high during trading on Tuesday . The stock traded as high as $12.62 and last traded at $12.27, with a volume of 32949 shares trading hands. The stock had previously closed at $12.51.

Wall Street Analysts Forecast Growth

FSNUY has been the subject of several analyst reports. Morgan Stanley reiterated an “overweight” rating on shares of Fresenius SE & Co. KGaA in a research note on Thursday, May 15th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Fresenius SE & Co. KGaA in a research report on Monday, February 3rd.

Fresenius SE & Co. KGaA Stock Down 1.9%

The stock’s 50-day moving average price is $11.34 and its two-hundred day moving average price is $10.09. The stock has a market capitalization of $27.41 billion, a P/E ratio of 64.58 and a beta of 0.78. The company has a current ratio of 1.36, a quick ratio of 1.05 and a debt-to-equity ratio of 0.57.

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) last released its earnings results on Wednesday, May 7th. The company reported $0.23 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $0.01. The company had revenue of $5.92 billion for the quarter, compared to the consensus estimate of $5.41 billion. As a group, research analysts expect that Fresenius SE & Co. KGaA will post 0.79 earnings per share for the current fiscal year.

Fresenius SE & Co. KGaA Increases Dividend

The firm also recently disclosed a dividend, which will be paid on Wednesday, June 4th. Investors of record on Wednesday, May 28th will be issued a $0.1827 dividend. The ex-dividend date is Tuesday, May 27th. This is an increase from Fresenius SE & Co. KGaA’s previous dividend of $0.17. This represents a yield of 1.48%. Fresenius SE & Co. KGaA’s dividend payout ratio (DPR) is 94.74%.

About Fresenius SE & Co. KGaA

Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.